Point: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? Yes

Chest. 2014 Jan;145(1):14-17. doi: 10.1378/chest.13-2354.

Authors

John P Corcoran¹, Najib M Rahman²

Affiliations

¹ Oxford Centre for Respiratory Medicine, Oxford University Hospitals, Oxford, England; Oxford Respiratory Trials Unit, University of Oxford, Oxford, England.
² Oxford Centre for Respiratory Medicine, Oxford University Hospitals, Oxford, England; Oxford Respiratory Trials Unit, University of Oxford, Oxford, England; NIHR Oxford Biomedical Research Centre, Oxford, England. Electronic address: [email protected].

PMID: 24394816
DOI: 10.1378/chest.13-2354

No abstract available

MeSH terms

Administration, Topical
Drainage / methods*
Empyema, Pleural / therapy*
Fibrinolytic Agents / therapeutic use*
Humans
Pleural Effusion / therapy*
Streptokinase / therapeutic use
Tissue Plasminogen Activator / therapeutic use
Urokinase-Type Plasminogen Activator / therapeutic use

Substances

Fibrinolytic Agents
Streptokinase
Tissue Plasminogen Activator
Urokinase-Type Plasminogen Activator